US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neo-Concept International Group Holdings Limited

1.42

-0.5000-26.04%

Volume:511.00K

Turnover:735.19K

Market Cap:5.77M

PE:5.21

High:1.59

Open:1.57

Low:1.27

Close:1.92

52wk High:8.15

52wk Low:0.9000

Shares:4.06M

Float Shares:945.20K

Volume Ratio:0.11

T/O Rate:54.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2723

EPS(LYR):0.2648

ROE:16.08%

ROA:6.19%

PB:0.77

PE(LYR):5.36

Loading ...

Overview Company News Filings

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference

JACOBIO-B (01167) Presents Preclinical Data for Pan-KRAS Inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

HUTCHMED (00013) Unveils HMPL-A251 Data at AACR-NCI-EORTC Conference

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":1.42,"timestamp":1765823454967,"preClose":1.92,"halted":0,"volume":510999,"delay":0,"floatShares":945200,"shares":4064000,"eps":0.272333,"marketStatus":"Trading","change":-0.5,"latestTime":"12-15 13:33:20 EST","open":1.57,"high":1.59,"low":1.27,"amount":735191.5330662,"amplitude":0.166667,"askPrice":1.49,"askSize":100,"bidPrice":1.3,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.272333,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765832400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":1.92,"preHourTrading":{"tag":"盘前","latestPrice":1.5403,"preClose":1.92,"latestTime":"09:29 EST","volume":64733,"amount":101735.6256736,"timestamp":1765808979804},"postHourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.92,"latestTime":"19:59 EST","volume":2368228,"amount":4561407.3924,"timestamp":1765587596200},"volumeRatio":0.110746},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":945200,"roa":"6.19%","roe":"16.08%","lyrEps":0.264768,"volumeRatio":0.110746,"shares":4064000,"dividePrice":0,"high":1.59,"amplitude":0.166667,"preClose":1.92,"low":1.27,"week52Low":0.9,"pbRate":"0.77","psRate":"0.21","week52High":8.15,"institutionHeld":0.7857,"latestPrice":1.42,"committee":-0.6,"eps":0.272333,"divideRate":0,"volume":510999,"delay":0,"ttmEps":0.272333,"open":1.57,"prevYearClose":3.3,"prevWeekClose":1.92,"prevMonthClose":1.17,"prevQuarterClose":1.83,"fiveDayClose":1.14,"twentyDayClose":0.9999,"sixtyDayClose":1.944},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-16","symbol":"NCI","defaultRemindTime":1750080600000,"type":"split","dateTimestamp":1750046400000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-12-12","current":7.050192,"percent":0.09466,"low":-615.963293,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"high":50.092968,"avg":7.676551,"sd":39.888864,"marketCap":5039382},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":25.951993,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":14650720},{"date":"2024-06-07","current":26.211896,"twenty":-81.702314,"median":25.015338,"eighty":34.642796,"marketCap":14813280},{"date":"2024-06-14","current":29.519581,"twenty":-78.809845,"median":25.103888,"eighty":32.998302,"marketCap":16682720},{"date":"2024-06-21","current":25.962557,"twenty":-75.44284,"median":25.889128,"eighty":31.491027,"marketCap":14685264},{"date":"2024-06-28","current":22.645555,"twenty":-74.134092,"median":25.192438,"eighty":30.05782,"marketCap":12803632},{"date":"2024-07-05","current":22.365126,"twenty":-73.07826,"median":25.015338,"eighty":29.519581,"marketCap":12639040},{"date":"2024-07-12","current":23.313894,"twenty":-71.810291,"median":24.273321,"eighty":28.980357,"marketCap":13183616},{"date":"2024-07-19","current":21.771249,"twenty":-70.527871,"median":24.005484,"eighty":28.783514,"marketCap":12305792},{"date":"2024-07-26","current":19.871565,"twenty":-67.981499,"median":23.548157,"eighty":28.579978,"marketCap":11236980},{"date":"2024-08-02","current":17.380948,"twenty":-63.611082,"median":23.313894,"eighty":28.402846,"marketCap":9828784},{"date":"2024-08-09","current":14.824233,"twenty":14.824233,"median":22.666232,"eighty":28.339976,"marketCap":8393176},{"date":"2024-08-16","current":14.891311,"twenty":14.824233,"median":22.428658,"eighty":26.393551,"marketCap":8432800},{"date":"2024-08-23","current":16.505019,"twenty":14.824233,"median":21.843651,"eighty":26.38192,"marketCap":9347200},{"date":"2024-08-30","current":15.221442,"twenty":14.891311,"median":21.615595,"eighty":26.235018,"marketCap":8617712},{"date":"2024-09-06","current":14.786956,"twenty":14.816778,"median":21.03365,"eighty":26.21652,"marketCap":8375904},{"date":"2024-09-13","current":18.291286,"twenty":14.783803,"median":19.997266,"eighty":26.012425,"marketCap":10355072},{"date":"2024-09-20","current":25.287335,"twenty":14.816778,"median":19.871565,"eighty":26.012425,"marketCap":14325600},{"date":"2024-09-27","current":18.961375,"twenty":14.877895,"median":19.084343,"eighty":25.954106,"marketCap":10769600},{"date":"2024-10-04","current":21.913118,"twenty":15.042266,"median":20.067523,"eighty":26.126798,"marketCap":12454128},{"date":"2024-10-11","current":22.176748,"twenty":15.165199,"median":20.049509,"eighty":25.99115,"marketCap":12598400},{"date":"2024-10-18","current":32.898839,"twenty":15.206634,"median":20.803771,"eighty":26.126798,"marketCap":18694400},{"date":"2024-10-25","current":23.358148,"twenty":15.219487,"median":21.352319,"eighty":26.21652,"marketCap":13270992},{"date":"2024-11-01","current":27.487373,"twenty":15.232907,"median":21.771249,"eighty":26.583872,"marketCap":15603728},{"date":"2024-11-08","current":26.826792,"twenty":15.38624,"median":21.882165,"eighty":26.827702,"marketCap":15231872},{"date":"2024-11-15","current":22.217928,"twenty":15.464941,"median":22.207911,"eighty":26.517352,"marketCap":12598400},{"date":"2024-11-22","current":19.532206,"twenty":15.526206,"median":22.192329,"eighty":26.402839,"marketCap":11076432},{"date":"2024-11-29","current":19.712189,"twenty":15.580772,"median":21.882165,"eighty":26.386572,"marketCap":11184128},{"date":"2024-12-06","current":18.691913,"twenty":15.639248,"median":21.771249,"eighty":26.293779,"marketCap":10607040},{"date":"2024-12-13","current":18.611126,"twenty":15.691094,"median":21.352319,"eighty":26.221145,"marketCap":10566400},{"date":"2024-12-20","current":7.102414,"twenty":15.639248,"median":20.803771,"eighty":26.151136,"marketCap":10058400},{"date":"2024-12-27","current":7.471029,"twenty":15.444399,"median":20.742686,"eighty":26.108587,"marketCap":10592816},{"date":"2025-01-03","current":10.196837,"twenty":15.213623,"median":20.067523,"eighty":26.07693,"marketCap":14427200},{"date":"2025-01-10","current":10.034934,"twenty":14.891311,"median":20.043836,"eighty":25.962557,"marketCap":14183360},{"date":"2025-01-17","current":9.907617,"twenty":14.749465,"median":19.895277,"eighty":25.951993,"marketCap":14008608},{"date":"2025-01-24","current":9.563114,"twenty":13.631492,"median":19.697706,"eighty":25.85141,"marketCap":13512800},{"date":"2025-01-31","current":8.48834,"twenty":10.018271,"median":19.532206,"eighty":25.746589,"marketCap":11988800},{"date":"2025-02-07","current":7.730432,"twenty":9.882149,"median":19.361654,"eighty":25.46422,"marketCap":10919968},{"date":"2025-02-14","current":7.130829,"twenty":9.483748,"median":19.090069,"eighty":25.309589,"marketCap":10081768},{"date":"2025-02-21","current":7.314786,"twenty":8.865676,"median":18.969464,"eighty":25.26403,"marketCap":10361168},{"date":"2025-02-28","current":5.889209,"twenty":8.594149,"median":18.858804,"eighty":25.21486,"marketCap":8333232},{"date":"2025-03-07","current":6.028973,"twenty":8.100004,"median":18.691913,"eighty":25.173677,"marketCap":8536432},{"date":"2025-03-14","current":5.598897,"twenty":7.846255,"median":18.496802,"eighty":25.10156,"marketCap":7926832},{"date":"2025-03-21","current":5.968988,"twenty":7.540872,"median":18.291286,"eighty":25.033931,"marketCap":8451088},{"date":"2025-03-28","current":7.03753,"twenty":7.389256,"median":18.105135,"eighty":24.856699,"marketCap":9956800},{"date":"2025-04-04","current":6.201809,"twenty":7.119463,"median":17.654152,"eighty":24.701604,"marketCap":8778240},{"date":"2025-04-11","current":6.159082,"twenty":7.009081,"median":17.557752,"eighty":24.560727,"marketCap":8737600},{"date":"2025-04-17","current":6.305413,"twenty":6.892251,"median":17.348506,"eighty":24.472151,"marketCap":8938768},{"date":"2025-04-25","current":5.299322,"twenty":6.518915,"median":16.836333,"eighty":24.40328,"marketCap":7518400},{"date":"2025-05-02","current":4.437465,"twenty":6.31653,"median":16.510738,"eighty":24.325687,"marketCap":6301232},{"date":"2025-05-09","current":5.171449,"twenty":6.285391,"median":16.156269,"eighty":24.224718,"marketCap":7317232},{"date":"2025-05-16","current":6.695699,"twenty":6.181855,"median":15.685852,"eighty":24.063819,"marketCap":6908800},{"date":"2025-05-23","current":7.021962,"twenty":6.235146,"median":15.538955,"eighty":24.008491,"marketCap":7233920},{"date":"2025-05-30","current":8.164705,"twenty":6.285272,"median":15.423857,"eighty":24.005032,"marketCap":8397532},{"date":"2025-06-06","current":8.847265,"twenty":6.289683,"median":15.216555,"eighty":23.931629,"marketCap":9092468},{"date":"2025-06-13","current":8.179292,"twenty":6.306628,"median":15.080005,"eighty":23.644242,"marketCap":8402196},{"date":"2025-06-20","current":10.670242,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"marketCap":10960400},{"date":"2025-06-27","current":11.716334,"twenty":6.315883,"median":14.760327,"eighty":23.456094,"marketCap":12034985},{"date":"2025-07-03","current":10.216346,"twenty":6.317177,"median":14.71349,"eighty":23.384943,"marketCap":10494000},{"date":"2025-07-11","current":10.261711,"twenty":6.410478,"median":11.716334,"eighty":23.359949,"marketCap":10540640},{"date":"2025-07-18","current":9.808428,"twenty":6.454657,"median":10.875077,"eighty":23.322745,"marketCap":10077038},{"date":"2025-07-25","current":9.671429,"twenty":6.462794,"median":10.624987,"eighty":23.130117,"marketCap":9934320},{"date":"2025-08-01","current":8.89955,"twenty":6.57431,"median":10.442049,"eighty":23.054884,"marketCap":9141440},{"date":"2025-08-08","current":8.26371,"twenty":6.676961,"median":10.261711,"eighty":22.850835,"marketCap":8488480},{"date":"2025-08-15","current":8.020396,"twenty":6.711807,"median":10.206559,"eighty":22.709857,"marketCap":8255280},{"date":"2025-08-22","current":7.944228,"twenty":6.718226,"median":10.054926,"eighty":22.653826,"marketCap":8198379},{"date":"2025-08-29","current":7.484931,"twenty":6.73937,"median":9.97069,"eighty":22.584141,"marketCap":7742240},{"date":"2025-09-05","current":9.159836,"twenty":6.821347,"median":9.934593,"eighty":22.562922,"marketCap":9467920},{"date":"2025-09-12","current":9.23611,"twenty":6.883125,"median":9.907617,"eighty":22.500907,"marketCap":9561200},{"date":"2025-09-19","current":8.862273,"twenty":6.893296,"median":9.771265,"eighty":22.442063,"marketCap":9188080},{"date":"2025-09-26","current":7.431141,"twenty":6.901678,"median":9.711704,"eighty":22.390539,"marketCap":7701314},{"date":"2025-10-03","current":7.413811,"twenty":6.942194,"median":9.659792,"eighty":22.276807,"marketCap":7680994},{"date":"2025-10-10","current":7.489961,"twenty":6.99974,"median":9.578721,"eighty":22.211918,"marketCap":7762274},{"date":"2025-10-17","current":7.128574,"twenty":6.974212,"median":9.51173,"eighty":22.189213,"marketCap":7396512},{"date":"2025-10-24","current":6.854291,"twenty":6.883125,"median":9.462569,"eighty":22.01857,"marketCap":7112031},{"date":"2025-10-31","current":6.186973,"twenty":6.854004,"median":9.33225,"eighty":21.875975,"marketCap":6421148},{"date":"2025-11-07","current":4.741629,"twenty":6.765339,"median":9.223624,"eighty":21.842138,"marketCap":4917461},{"date":"2025-11-14","current":4.19042,"twenty":6.696493,"median":9.126243,"eighty":21.797185,"marketCap":4348499},{"date":"2025-11-21","current":3.92273,"twenty":6.462068,"median":9.081059,"eighty":21.677857,"marketCap":4064018},{"date":"2025-11-28","current":4.258196,"twenty":6.343606,"median":9.054357,"eighty":21.613946,"marketCap":4754901},{"date":"2025-12-05","current":4.259674,"twenty":6.293615,"median":8.88422,"eighty":21.40415,"marketCap":4754901},{"date":"2025-12-12","current":4.514242,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"marketCap":5039382}],"updateTime":1765787466151},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2578641761","title":"ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578641761","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578641761?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:30","pubTimestamp":1761568200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  27, 2025  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that addres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174568/0/en/ORIC-Pharmaceuticals-Presented-Preclinical-Data-at-the-EORTC-NCI-AACR-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-Supporting-Best-in-Class-Potential-of-OR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1550","BK4202","BK1184","LU0456854461.SGD","LU0572940350.SGD","BK4139","LU0264606111.USD","CRC","BK4213","LENZ","BK1584","LU0266512127.USD","BK4007","AR","ORIC","NCI","01336","BK4539","LU0572939691.SGD"],"gpt_icon":0},{"id":"2578457986","title":"Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578457986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578457986?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:00","pubTimestamp":1761566400,"startTime":"0","endTime":"0","summary":"Fort Lee, NJ, Oct.  27, 2025  (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/27/3174533/0/en/Nuvectis-Pharma-Provides-Poster-Presentation-Highlights-for-NXP900-from-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","NVCT","BK4007","LU0264606111.USD","BK4202","LENZ","01336","BK1584","BK1550","BK1184","LU0572939691.SGD","BK4139","BK4539","LU0572940350.SGD"],"gpt_icon":0},{"id":"2578097955","title":"Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2578097955","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578097955?lang=en_us&edition=fundamental","pubTime":"2025-10-26 01:14","pubTimestamp":1761412440,"startTime":"0","endTime":"0","summary":"First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and maximize tumor controlLONDON and PHILADELPHIA, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/25/3174179/0/en/Avacta-presents-first-preclinical-data-from-dual-payload-pre-CISION-medicines-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4548","IE00BYQNZ168.SGD","BK4535","BK1584","NCI","BK4571","BK4531","LU1023057109.AUD","BK1184","01336","LU0572940350.SGD","BK4509","01698","BK4552","LU0359202008.SGD","BK4202","LU0359201612.USD","IE00B12V2V27.USD","LU2039709279.SGD","IE00BYTNYN87.SGD","SG9999011746.SGD","BK1550","TME","BK4565","LU0572939691.SGD","BK4108","BK4563","LU0456842615.SGD","LU0264606111.USD"],"gpt_icon":0},{"id":"2578509376","title":"Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2578509376","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578509376?lang=en_us&edition=fundamental","pubTime":"2025-10-26 00:30","pubTimestamp":1761409800,"startTime":"0","endTime":"0","summary":"Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/25/3174172/0/en/Preclinical-Data-Presented-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics-Support-Potential-of-BBO-10203-a-First-in-Class-RAS-PI3K.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GEM","LENZ","LU0264606111.USD","NCI","BK4539","LU0572940350.SGD","01336","BK4007","BK4202","BK1184","PDX","BK1550","BK1584","LU0572939691.SGD","CDX","BK4139"],"gpt_icon":0},{"id":"2578528627","title":"Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578528627","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578528627?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:00","pubTimestamp":1761336000,"startTime":"0","endTime":"0","summary":"– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3173061/0/en/Arvinas-Presents-Preclinical-Data-for-ARV-806-Demonstrating-Robust-and-Differentiated-Activity-in-Models-of-KRAS-G12D-mutated-Cancer-at-the-2025-AACR-NCI-EORTC-International-Confer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01336","NCI","LENZ"],"gpt_icon":0},{"id":"2578546906","title":"Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2578546906","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578546906?lang=en_us&edition=fundamental","pubTime":"2025-10-25 00:30","pubTimestamp":1761323400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and BOULDER, Colo., Oct.  24, 2025  (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3172997/0/en/Cogent-Biosciences-Announces-KRAS-Poster-Presentation-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348723411.USD","IE00BZ199S13.USD","BK1184","LU1548497426.USD","LU1720051108.HKD","BK4007","IE00BD6J9T35.USD","BK4605","LU2357305700.SGD","LU2298322129.HKD","LU1670627923.USD","LU1854104046.USD","NCI","ON","BK4588","LU0572939691.SGD","CCOI","BK4089","BK4139","LU1978683503.SGD","LU0124384867.USD","LU1861219969.SGD","BK4202","BK4532","BK1584","LU0724618433.USD","LU1670628061.USD","BK4585","LU0572940350.SGD","LU0264606111.USD","BK1550","01336","LU1854103824.USD","BK4512","LU1720051017.SGD","LU1861215975.USD","LENZ","LU1861214812.USD","BK4141","LU2360107325.USD","LU1861220033.SGD","BK4539","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2577451011","title":"Merus to present interim data on petosemtamab at AACR-NCI-EORTC conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577451011","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577451011?lang=en_us&edition=fundamental","pubTime":"2025-10-24 22:40","pubTimestamp":1761316825,"startTime":"0","endTime":"0","summary":"Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtam...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/merus-to-present-interim-data-on-petosemtamab-at-aacr-nci-eortc-conference-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/merus-to-present-interim-data-on-petosemtamab-at-aacr-nci-eortc-conference-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCI","BK4139","LU0889565916.HKD","MRUS","BK4202","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"1123570596","title":"JACOBIO-B (01167) Presents Preclinical Data for Pan-KRAS Inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1123570596","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123570596?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:14","pubTimestamp":1761257650,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) announced that it will present preclinical data for its oral, highly potent Pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK4202","NCI","01167"],"gpt_icon":0},{"id":"2577539014","title":"BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577539014","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577539014?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:05","pubTimestamp":1761249900,"startTime":"0","endTime":"0","summary":"Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172449/0/en/BBOT-Presents-Preclinical-Data-Demonstrating-Potential-of-BBO-11818-as-a-Potent-panKRAS-Inhibitor-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BBOT","01336"],"gpt_icon":0},{"id":"2577958432","title":"Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577958432","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577958432?lang=en_us&edition=fundamental","pubTime":"2025-10-24 00:30","pubTimestamp":1761237000,"startTime":"0","endTime":"0","summary":"Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172321/0/en/Zymeworks-Presents-Initial-Clinical-Data-from-the-Phase-1-trial-of-ZW191-an-Antibody-Drug-Conjugate-Targeting-Folate-Receptor-at-AACR-NCI-EORTC-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","BK4588","BK1584","BK4581","BK4561","01336","BK1550","BK4590","ADC","LU0572939691.SGD","BK4144","BK4231","BK4585","BK4202","BK4080","ET","ORR","BK1184","NCI","LU0572940350.SGD"],"gpt_icon":0},{"id":"2577584321","title":"ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577584321","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577584321?lang=en_us&edition=fundamental","pubTime":"2025-10-24 00:30","pubTimestamp":1761237000,"startTime":"0","endTime":"0","summary":"-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172323/0/en/ALX-Oncology-Announces-Preclinical-Data-and-Phase-1-Trial-in-Progress-Presentations-of-ALX2004-a-Novel-EGFR-Targeted-ADC-at-2025-AACR-NCI-EORTC-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572940350.SGD","LU2065732104.USD","LU0264606111.USD","ALX","BK4202","BK4231","ADC","LU0572939691.SGD","NCI","BK4080","BK1184","PRGS","BK4097","BK1550","BK1584","01336"],"gpt_icon":0},{"id":"1154600470","title":"HUTCHMED (00013) Unveils HMPL-A251 Data at AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1154600470","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154600470?lang=en_us&edition=fundamental","pubTime":"2025-10-23 08:21","pubTimestamp":1761178899,"startTime":"0","endTime":"0","summary":"HUTCHMED (00013) announced the presentation of preclinical data for HMPL-A251 at the AACR-NCI-EORTC Molecular Targeted Therapy and Cancer Treatment International Conference, held from October 22 to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","BK4202","BK4585","BK4588","BK1588","HCM","BK4007","BK1191","NCI","BK4531","BK1587"],"gpt_icon":0},{"id":"2577345425","title":"HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577345425","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577345425?lang=en_us&edition=fundamental","pubTime":"2025-10-23 08:00","pubTimestamp":1761177600,"startTime":"0","endTime":"0","summary":"— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — —Unique, highly potent PI3K/PIKK inh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3171612/0/en/HUTCHMED-Highlights-HMPL-A251-Data-Presented-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","LENZ","01336","BK1184","BK1587","BK1588","LU0572940350.SGD","BK4539","LU0572939691.SGD","BK4139","BK4007","LU0264606111.USD","NCI","00013","BK1191","BK1550","BK1584"],"gpt_icon":0},{"id":"2577332319","title":"Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332319","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332319?lang=en_us&edition=fundamental","pubTime":"2025-10-23 04:00","pubTimestamp":1761163200,"startTime":"0","endTime":"0","summary":"NEW HAVEN, Conn., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171450/0/en/Arvinas-to-Present-Preclinical-Data-for-ARV-806-a-PROTAC-KRAS-G12D-Degrader-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01336","BK4539","LU0572939691.SGD","BK4139","BK4202","LU0264606111.USD","NCI","BK1550","BK1184","LU0572940350.SGD","BK4007","BK1584","LENZ"],"gpt_icon":0},{"id":"2577041394","title":"I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577041394","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577041394?lang=en_us&edition=fundamental","pubTime":"2025-10-23 00:35","pubTimestamp":1761150900,"startTime":"0","endTime":"0","summary":"Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171382/0/en/I-Mab-To-Present-Positive-Updated-Givastomig-Monotherapy-Data-at-2025-AACR-NCI-EORTC-Molecular-Targets-and-Cancer-Therapeutics-Conference-on-October-23-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0572940350.SGD","LU0264606111.USD","LENZ","BK4139","BK4535","BK1550","SD","ORR","BK4213","BK4225","BK4202","HR","BK4539","BK4007","BK4203","01336","PR","LU0572939691.SGD","IMAB","BK4526","BK1584","BK4505","BK1184","NCI"],"gpt_icon":0},{"id":"2575291296","title":"I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291296","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291296?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439600,"startTime":"0","endTime":"0","summary":"The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct.  14, 2025  (GLOBE NEWSWIRE) -- I-Mab (NA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166006/0/en/I-Mab-to-Present-Short-Talk-on-Updated-Givastomig-Monotherapy-Data-at-the-2025-AACR-NCI-EORTC-Molecular-Targets-and-Cancer-Therapeutics-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1550","01336","BK4139","BK4526","NCI","LENZ","LU0264606111.USD","BK4535","BK1184","BK4007","BK4202","LU0572939691.SGD","BK4505","BK1584","LU0572940350.SGD","BK4539","IMAB"],"gpt_icon":0},{"id":"2575428062","title":"Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575428062","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575428062?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":"Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- Zent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165795/0/en/Zentalis-Pharmaceuticals-Announces-Four-Azenosertib-Posters-Presentations-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1550","BK1584","BK4202","LU0572939691.SGD","LU0264606111.USD","LU0572940350.SGD","BK4007","01336","PROC","BK4539","NCI","BK4139","LENZ","BK1184"],"gpt_icon":0},{"id":"2575280607","title":"Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280607","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280607?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Oct.  13, 2025  (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165792/0/en/Boundless-Bio-Announces-Upcoming-Presentation-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0077335932.USD","BK4539","BK1184","LU2244417387.USD","BK4019","BK4139","LENZ","BK4007","BOLD","LU0572940350.SGD","LU2413666699.HKD","LU2413666426.HKD","BK4202","BK1550","LU0572939691.SGD","LU0187121727.USD","LU0347712357.USD","LU1721428933.USD","NCI","01336","LU0264606111.USD","BK1584","RNR"],"gpt_icon":0},{"id":"2575543280","title":"PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575543280","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575543280?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:01","pubTimestamp":1760385660,"startTime":"0","endTime":"0","summary":"Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harbor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165785/0/en/PMV-Pharmaceuticals-to-Present-Rezatapopt-Pivotal-Phase-2-Initial-Analysis-and-Natural-History-Study-Results-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Target.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0264606111.USD","BK1584","BK4139","BK4202","LU0572939691.SGD","LENZ","PMVP","BK4007","BK4539","NCI","LU0572940350.SGD","BK1550","01336","BK1184"],"gpt_icon":0},{"id":"2575028051","title":"Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575028051","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575028051?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:00","pubTimestamp":1760385600,"startTime":"0","endTime":"0","summary":"Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165776/0/en/Zymeworks-to-Present-Clinical-Data-from-the-Phase-1-trial-of-ZW191-an-Antibody-Drug-Conjugate-Targeting-Folate-Receptor-at-AACR-NCI-EORTC-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","NCI","BK4144","BK1184","BK4590","BK4561","01336","BK4202","ET","BK4581","BK4585","LU0572939691.SGD","BK1584","BK4080","LU0264606111.USD","LU0572940350.SGD","BK4588","ADC","BK1550"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}]}}